VIVUS Inc. (VVUS) Soars after Getting an Outperform Rating from Wedbush

Shares of VIVUS Inc. (NASDAQ: VVUS) continued yesterday’s ascent in early trading, up 1.11% to $11.82 shortly after the opening bell. VVUS closed 9.56% higher at $11.69, with volume up from daily average of 4.67 million to 12.78 million. The stock was active again in after-hours trading today. It fell 0.77% to $11.60 in after-hours trading.

VIVUS  has a 52-week range of $5.55-$13.68. It is currently trading above its 50-day and 200-day moving averages of $11.19 and $9.57, respectively. The stock has seen support at $9.76. It has broken through its resistance level of $11.41 in Thursday’s trading.

Wedbush recently initiated coverage on the VIVUS with an Outperform rating. Wedbush has set a price target of $20 on the VIVUS  stock. The stock has a consensus recommendation of Outperform. Currently, it has 1 Buy, 5 Outperform and 6 Hold ratings.

VIVUS  is likely to be in the news over the next few days as its drug candidate for obesity, Qnexa, will come up for review with the U.S. FDA on July 15. If Qnexa is approved by the U.S. FDA, it will be the first prescription drug for the treatment of obesity in a decade in the U.S.

Going by the past history of drugs for treatment of obesity that have come up for review by the FDA, the future for FDA approval is questinable. According to Reuters report, in the past, pills for obesity have not been approved by the FDA, or have received severe warnings, or have been taken off the market.

Apart from Qnexa, VIVUS’ other drug candidate, Avanafil, is in phase 3 trials for erectile dysfunction.

About BeaconEquity.com

BeaconEquity.com is committed to producing the highest-quality insight and analysis of small cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily on the underserved OTC stocks market, or “penny stock” market, which has traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.

Bookmark and Share

7 Comments »

Trackbacks

  1. FDA to review 3 new diet pills – Fort Wayne Journal Gazette | Weight-Loss-HQ.com
  2. FDA to review 3 new diet pills – Fort Wayne Journal Gazette | DietNox.com
  3. FDA to review 3 new diet pills – Fort Wayne Journal Gazette | Health-Diet-Expert.com
  4. FDA to review 3 new diet pills – Fort Wayne Journal Gazette | Weight-Loss-Base.com
  5. FDA to review 3 new diet pills – Fort Wayne Journal Gazette | Fat-Burn-HQ.com
  6. FDA to review 3 new diet pills – Fort Wayne Journal Gazette | FatBurnBase.com
  7. FDA to review 3 new diet pills – Fort Wayne Journal Gazette | WeightLossNox.com

Add Your Comment

Copyright Beacon Equity @ 2010

Google Analytics Alternative Clicky